Common Stock, par value $0.001
- Symbol
- SBFM
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 5.07 · 8-K
Sunshine Biopharma Inc.
SBFMNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On October 13, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent:…
Company context
We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc., a Canadian corporation, through which we currently have 60 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc., a Canadian corporation through which we develop and sell OTC supplements.
Current securities
Historical securities (6)
SBFMOTC · EQUITY · Historical · closed Feb 1, 2019SBFMOTC · EQUITY · Historical · closed Apr 6, 2020SBFMOTC · EQUITY · Historical · closed Feb 9, 2022SBFMDOTC · EQUITY · Historical · closed Mar 1, 2019SBFMDOTC · EQUITY · Historical · closed May 1, 2020SBFMDOTC · EQUITY · Historical · closed Feb 15, 2022
Registered securities in this filing
SUNSHINE BIOPHARMA INC. · 8-K · Filed 2026-10-14
Common Stock Purchase Warrants
- Symbol
- SBFMW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of
Security Holders.
On October 13, 2026, Dr. Steve N. Slilaty, as
the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by
written consent:
to issue in excess of twenty percent (20%) of the outstanding shares of the Company’s common stock
at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the
Placement Agent Agreement for the Company’s public offering that closed on October 9, 2026 (the “Offering”).
to any adjustment to the exercise price or number of shares of common stock underlying the Series D Warrants
issued in the Offering in the event of a Share Combination Event pursuant to Section 3.7 of the Series D Warrants.
to the voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding
Series D Warrants pursuant to Section 3.8 of the Series D Warrants.
The shareholder consent will be effective 20 days
after the definitive information statement relating to such consent is mailed to stockholders. Dr. Slilaty, who is the Company’s
chief executive officer, holds approximately 90% of the total voting power of the Company’s stockholders.